Watch: We expect big numbers to kick in from FY20-FY21,Kiran Mazumdar Shaw, Biocon
Talking to ET Now, Kiran Mazumdar Shaw, Biocon , says betting big on biosimilars and trastuzumab. Shaw says it is a huge opportunity for the company and she expects big numbers because there is going to be a ramp-up phase.
Other Expert Views Videos
Smallcap investing: timing, risk, and returns | Golden Thumb Rule ft Aniruddha Naha
Market fall sparks buy call: Prateek Agrawal on why this dip may be an opportunity
The Golden Thumb Rule | Should you pause your SIP in a market fall? checklist inside
First in Motilal Oswal AMC investing series: QGLP principles for disciplined investing
Rebalance when asset weights drift, not when headlines shout: DSP CEO Kalpen Parekh